Shares of Morgan Stanley and Goldman Sachs fell sharply after reports suggested OpenAI's IPO could be delayed, impacting the banks' underwriting fee expectations.
Morgan Stanley shares fell on reports that OpenAI's IPO is facing a possible delay. As a lead underwriter, a postponement reduces the bank's near-term fee income outlook.
While exact figures are not disclosed, large tech IPOs can generate tens of millions in underwriting fees, having a material but not dominant impact on investment banking revenue.
The stock decline reflects near-term sentiment; long-term investors may weigh the bank's diversified revenue streams and pipeline of other deals.
Investors will watch for updates on the IPO timeline, Q2 earnings from the bank, and other tech IPOs.
Goldman Sachs stock dipped on news that the OpenAI IPO might be postponed. Goldman is also expected to be a key underwriter, and the delay dampens the revenue outlook for its investment banking division.
Goldman Sachs is expected to be a lead underwriter, so a delay directly impacts its investment banking fee pipeline in the near term.
Both are lead underwriters, but without specific fee disclosures their relative impact is similar. Goldman's broader investment banking franchise may cushion the blow.
Key watch points are any official statement from OpenAI, Goldman's quarterly earnings report, and developments in other large tech IPOs.
Morgan Stanley and Goldman Sachs shares declined on reports that OpenAI's anticipated IPO may be postponed. The delay threatens fee income for the banks that were slated to underwrite the landmark tech listing. The sell-off reflects market concerns over reduced investment banking revenue streams.
The shares fell due to reports that OpenAI's planned IPO may be postponed, which would reduce expected underwriting fees for the banks.
The OpenAI IPO was expected to be one of the largest tech IPOs, generating substantial fees for the leading underwriters. A delay removes a near-term revenue catalyst.
Possible reasons include market volatility, regulatory hurdles, or internal company readiness, though the article may not specify.